Heyholder
‹ Activism Filings

ChoA Pharmaceutical Co., LTD. Q3 operating loss of KRW 0.3 billion on revenue of KRW 13.8 billion

ChoA Pharmaceutical Co., LTD.· Periodic Report

AI summary · Not investment advice

Joa Pharm sold KRW 13.8 billion in Q3 but lost KRW 0.3 billion from its main business; sales fell 10.7% from a year earlier and 9.0% from the prior quarter.

Operating profit · 3 months

KRW -251.2 million

Key facts

Revenue (3 months)
KRW 13.8 billion
Net income (3 months)
KRW -472.5 million
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 15.5 billion
Revenue (year to date)
KRW 43.7 billion
Operating profit (prior-year 3 months)
KRW -1.5 billion
Operating profit (year to date)
KRW -1.4 billion
Net income (prior-year 3 months)
KRW -414.6 million
Net income (year to date)
KRW -245.9 million

Commentary

AI commentary · Not investment advice

What happened

Choa Pharmaceutical reported its consolidated results for the 3rd quarter of 2026. Sales for the 3 months were KRW 13.82 billion. That is 10.7% lower than the same 3 months a year earlier (KRW 15.48 billion) and 9.0% lower than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was a loss of KRW 251.2 million. A year earlier, the same period showed a loss of KRW 1.49 billion. Net income (final profit after taxes and all other costs) was a loss of KRW 472.5 million, a swing to a loss from the previous quarter. A year earlier, the net loss was KRW 414.6 million.

What changes for shareholders

For the year to date (January 1 to September 30), sales were KRW 43.69 billion. Operating profit was a loss of KRW 1.39 billion. Net income was a loss of KRW 245.9 million.

Comments

No comments yet

Comments from shareholders will appear here.